# Zymeworks Announces Participation in Upcoming Investor Conferences

- Published: 2026-11-19
- Author: [Zymeworks Inc.](https://healthcarenews.io/news/zymeworks-announces-participation-in-upcoming-investor-conferences.md)
- Press release: [Read the release](<https://www.globenewswire.com/news-release/2026/11/19/3406382/0/en/zymeworks-announces-participation-in-upcoming-investor-conferences.html>)
- Topics: [News](https://healthcarenews.io/news.md)
- Source: https://healthcarenews.io/news/zymeworks-announces-participation-in-upcoming-investor-conferences/
- Publication: Healthcare News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://healthcarenews.io/editorial-policy/

VANCOUVER, British Columbia, Nov. 19, 2026 [(GLOBE NEWSWIRE)](https://www.globenewswire.com) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced will participate in the following upcoming investor conferences:

-   Evercore Healthcare Conference: Management will participate in one-on-one meetings and a fireside chat on November 30 at 2:10 pm Eastern Time (ET) in Miami, FL
-   Citi’s 2026 Global Healthcare Conference: Management will participate in one-on-one meetings and a fireside chat on December 1 at 3:40 pm ET in Miami, FL

A live webcast of certain fireside chats will be available in the Investors section of the Zymeworks website at <a href="https://www.globenewswire.com/Tracker?data=GB8beiQ1xnXrC3Z8vFF3lc8V-EjMn12RAKxvC1Vo4AQa6Z84Po7aOHifs21P4dnujxV_n8dRTadK-F3ZzcDqKA5GHQQl2o0OfUtWXnq0_q4=" rel="nofollow">www.zymeworks.com</a>, and a replay will be available following the events.

**About Zymeworks Inc.**

Zymeworks is a global biotechnology company building a diversified portfolio of healthcare assets designed to generate durable cash flows while advancing innovative medicines for difficult-to-treat diseases. The Company’s asset and royalty aggregation strategy combines a growing portfolio of commercial and near-commercial assets, including YUPELRI® (revefenacin), with a differentiated internal research and development engine. Zymeworks’ portfolio also includes Ziihera® (zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by Zymeworks and commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines, and pasritamig, a clinical-stage multispecific antibody developed by Johnson & Johnson using Zymeworks’ proprietary antibody engineering technologies.

Zymeworks is advancing a diverse pipeline of novel biotherapeutics, leveraging its proprietary Azymetric™ platform and expertise in antibody-drug conjugates, multispecific antibodies and other next-generation antibody technologies. These capabilities, together with Zymeworks’ integrated drug development expertise, enable the Company to develop differentiated therapeutics and create value through both internal innovation and strategic partnerships.

For more information about Zymeworks, its portfolio and pipeline, visit <a href="https://www.globenewswire.com/Tracker?data=GB8beiQ1xnXrC3Z8vFF3lYxU7LVAyvHyFyEOPkeULOxnTzS0qrdt_D1D8y-WcdcNZmLYDZwZyM6n7wx0OxKa5s9YUa-OcQyYFcY9O2Wmptw=" rel="nofollow">www.zymeworks.com</a> and follow @ZymeworksInc on X.

**Contacts:**

Investor Inquiries:  
Shrinal Inamdar  
Vice President, Investor Relations  
(604) 678-1388  
<a href="https://www.globenewswire.com/Tracker?data=ASrE_jrWAVXNxT8FDP8uMtUNIBe6IrfMMGI_V2AzEIrCj4umTmNrGMk13Q8jBe2_bXH97gWMKE1EnMTwVMFkyeOTVaP2DfgIR85IFGvDIKQ=" rel="nofollow">ir@zymeworks.com</a>

Media Inquiries:  
Diana Papove  
Vice President, Corporate Communications  
(604) 678-1388  
<a href="https://www.globenewswire.com/Tracker?data=vkRzVFq5TUPR2e5ki8zfT2pszpfLWwweTqx370TrpFeT_kUvHvcOS-fBnkchU27JgqNgZfgORZBz66IYoUlYcqyX0blcjKRkGTkOAxohPig=" rel="nofollow">media@zymeworks.com</a>

  
![](https://ml.globenewswire.com/media/MjM5ODdkYzAtNzI2Zi00ZDBhLWIxYjctOTE1YzI2Zjk2NjVjLTEyNjg0NDItMjAyNi0xMS0xOS1lbg==/tiny/Zymeworks-Inc-.png)

## Related

- [Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://healthcarenews.io/news/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4.md)
- [Press Release: Sanofi’s Infilbray approved in the US as the first medicine to treat neurological manifestations of Type 3 Gaucher disease](https://healthcarenews.io/news/press-release-sanofis-infilbray-approved-in-the-us-as-the-first-medicine-to-treat-neurolog.md)
- [Palvella Therapeutics to Host Webcast to Introduce New QTORIN™ Program](https://healthcarenews.io/news/palvella-therapeutics-to-host-webcast-to-introduce-new-qtorin-program.md)
- [Teva Announces R&D Leadership Transition; Eric Hughes to Depart the Company](https://healthcarenews.io/news/teva-announces-r-d-leadership-transition-eric-hughes-to-depart-the-company.md)
